Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Inclusion Criteria: * Age: 18-75 * ECOG score: 0 or 1 * Unresectable advanced or recurrent gastric cancer/gastroesophageal junction cancer * histologically proven adenocarcinoma * Received chemotherapy based on platinum and fluorouracil within 12 months * Patients not previously treated with paclitaxel or irinotecan * Liver function: total bilirubin, ALT and AST\<1.5 × ULN (Normal Value upper limit) * Renal function: Cr\<1.5 × ULN and creatinine clearance ≥ 40 ml/min * Echocardiography or radionuclide cardiac function test, LVEF ≥ 50% * Expected survival ≥ 3 months * Sign the informed consent form Exclusion Criteria: * Patients who have received irinotecan or paclitaxel chemotherapy in the past * ECOG PS score:\>2 * Advanced gastric cancer patients with extensive and severe peritoneal metastasis * Patients with severe liver and kidney insufficiency or cardiac insufficiency * HIV positive, active hepatitis B or C, active pulmonary tuberculosis * Patients with active autoimmune diseases, including lupus erythematosus, rheumatoid arthritis, rheumatoid arthritis, etc * Patients known to be allergic to any of the study drugs * Pregnant or lactating female patients